In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Key Takeaways A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its ...

Sanofi and Regeneron said that drug candidate Itepekimab didn’t meet primary endpoint in a phase three study, although a ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Sanofi and Regeneron on Friday reported lackluster late-stage results for their drug candidate in a common lung condition, ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition commonly ...

Sanofi and Regeneron Pharmaceuticals reported mixed results for two late-stage trials of an experimental respiratory drug they are jointly developing, with one study meeting the primary goal and a ...